通鼎互聯(002491.SZ):參股的雲創數據為股轉系統精選層掛牌公司
格隆匯11月2日丨通鼎互聯(002491.SZ)發佈股票交易異常波動公吿,公司參股南京雲創大數據科技股份有限公司。截至公吿日,公司持有雲創數據18,157,407股,佔其總股本的13.72%。雲創數據為全國中小企業股份轉讓系統精選層掛牌公司。2021年10月30日,證監會對《關於全國中小企業股份轉讓系統掛牌公司轉板上市的指導意見》作了修訂,形成《關於北京證券交易所上市公司轉板的指導意見》,並向社會公開徵求意見。
公司控股股東或第一大股東及其一致行動人質押股份數量佔其所持公司股份數量比例超過80%,請投資者注意相關風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.